FLT3 and acute myeloid leukemia: Although gilteritinib (type 1 FLT3 inhibitor) is the only FDA‐approved FLT3 inhibitor to treat patients with FLT3‐mutated R/R AML, a perusal of the literature showed no direct comparisons among FLT3 inhibitors in the treatment of patients with R/R AML.